about
Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma.Real-life Efficacy of Omalizumab After 9 Years of Follow-up.Prospects for new and emerging therapeutics in severe asthma: the role of biologics.Effects of Immunoglobulin Replacement on Asthma Exacerbation in Adult Asthmatics with IgG Subclass Deficiency.Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?Neutrophil Extracellular DNA Traps Induce Autoantigen Production by Airway Epithelial Cells.Serum vascular endothelial growth factor as a marker of asthma exacerbation.Bronchial thermoplasty and the role of airway smooth muscle: are we on the right direction?Clinical Characteristics of Exacerbation-Prone Adult Asthmatics Identified by Cluster Analysis.Epithelial folliculin is involved in airway inflammation in workers exposed to toluene diisocyanate.Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty.Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea.Update in Asthma 2016.Dupilumab for the treatment of asthma.Effects of Anti-IL-17 on Inflammation, Remodeling, and Oxidative Stress in an Experimental Model of Asthma Exacerbated by LPS.Is Omalizumab a Problem-Solving Remedy in Severe Asthma?Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history.TRPV1 Blocking Alleviates Airway Inflammation and Remodeling in a Chronic Asthma Murine Model.Role of clusterin/progranulin in toluene diisocyanate-induced occupational asthma.Perceptions of Severe Asthma and Asthma-COPD Overlap Syndrome Among Specialists: A Questionnaire Survey.Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma.Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthmaAnti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response
P2860
Q38662759-58BA1546-7F48-4982-9560-15736503B474Q38789811-E8D13F14-F3E7-463E-821E-04FBB4A89A67Q39278773-A54A9D4C-2E3B-4D70-BAE1-AE1D2AB22B53Q40039287-E95ECC0F-780E-4B41-9031-E3CB00F34701Q41633977-B5552C2F-652A-4625-BD36-1EB04C6E80B3Q41689608-829B25AC-15CF-49C7-9942-2D0D873678ACQ42318006-7A180DD1-B6A6-4C10-ACB1-629715485D46Q42364415-E3273BF0-4447-40F8-A2EE-1E60B7DBFFC3Q42736756-AEA190D2-FA7B-4C68-A3FF-FF1B0E601493Q47393736-377CF022-89CD-4BB6-886E-DCC0ED53E0CDQ47595210-C67BD6F5-F27F-4688-9FDC-F7762607523EQ48091478-27AF3943-BAF8-47B5-80C6-E0339FA4E260Q48117000-3C56306D-35B2-45B4-B596-9F3C1BCA5615Q49486790-A03DCD3A-B6D5-4BC7-91AA-9851694C5F15Q49592657-FF26EE30-A022-464D-961C-ABBD1A865054Q50144899-6DE21244-E5C3-47D2-92F2-D1F1D3947CF8Q52584472-CFA27F32-5DD6-48A2-85CF-CFEC93360FD8Q52718023-BE31B9DF-3A95-405F-B456-7787C9039E7BQ53069735-72B5B170-48D5-43BA-9246-8FF8BC8BE615Q53072682-64CB699E-4D67-4DA7-81DC-9375F711EEDBQ55261545-BF454CB6-7A47-48F6-8C44-351F823BE2BBQ58774770-5573850D-DCC8-468C-9204-BA5A3FFCC0B9Q58816356-6DF026FC-5747-488F-B740-9AA37265D7D9
P2860
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Development of New Therapies for Severe Asthma
@ast
Development of New Therapies for Severe Asthma
@en
Development of New Therapies for Severe Asthma
@nl
type
label
Development of New Therapies for Severe Asthma
@ast
Development of New Therapies for Severe Asthma
@en
Development of New Therapies for Severe Asthma
@nl
prefLabel
Development of New Therapies for Severe Asthma
@ast
Development of New Therapies for Severe Asthma
@en
Development of New Therapies for Severe Asthma
@nl
P2860
P356
P1476
Development of New Therapies for Severe Asthma
@en
P2093
Merritt L. Fajt
Sally E. Wenzel
P2860
P356
10.4168/AAIR.2017.9.1.3
P407
P577
2017-01-01T00:00:00Z